The in vivo biodistributions of the monopotassium salt of hydroxyethylidenediphosphonate labeled with 188Re (188Re-KHEDP) were studied in rats for drug batches prepared with and without Re carrier. Also, the pharmacokinetics of two batches of 188Re-KHEDP that were synthesized at different temperatures (20 and 100°C) were studied. The results showed that all 188Re-KHEDP preparations accumulated in bone. The excretory pathway of 188Re-KHEDP was through the kidneys. Only kidney and thyroid exhibited a relatively high drug uptake among the soft tissue organs. The results showed that carrier-added 188Re-KHEDP had better pharmacokinetic parameters than the carrier-free radiopharmaceutical as manifested by higher bone uptake and faster blood clearance. It was also found that the presence of Re carrier increased significantly the stability of 188Re-KHEDP. The skeleton-to-muscle ratio was 249.1 ± 42.1 for carrier-added 188Re-KHEDP and <21 for the carrier-free drug. The biodistributions of 188Re-KHEDP differed for drugs prepared at 20 and 100°C. The maximum skeleton-to-muscle and skeleton-to-blood ratios were 157.3 ± 24.4 and 21.4 ± 4.85 for 188Re-KHEDP prepared at 20°C and 467.2 ± 123.2 and 77.9 ± 11.9 for that prepared at 100°C. These results showed a statistically significant difference (p < 0.05) in favor of 188Re-KHEDP prepared at 100°C. The results indicated that all versions of 188Re-KHEDP had promising properties as potential therapeutic bone-metastasis agents. However, carrier-added 188Re-KHEDP and that prepared at 100°C exhibited better properties than the other types of the examined radiopharmaceutical.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
L. J. Morin and J. C. Stevens, J. Urol., 97, 130 – 132 (1967).
R. G. Robinson, J. A. Spicer, D. F. Preston, et al., Nucl. Med. Biol., 14, 219 – 222 (1987).
N. O. Kucuk, E. Ibis, G. Aras, et al., Ann. Nucl. Med., 14(4), 239 – 245 (2000).
K. Liepe, R. Hliscs, J. Kropp, et al., Cancer Biother. Radiopharm., 15(3), 261 – 265 (2000).
W. Y. Lin, C. P. Lin, S. J. Yeh, et al., Eur. J. Nucl. Med., 24(6), 590 – 595 (1997).
B. T. Hsieh, J. F. Hsieh, S. C. Tsai, et al., Nucl. Med. Biol., 26, 973 – 976 (1999).
S. J. Oh, K. S. Won, D. H. Moon, et al., Nucl. Med. Commun., 23, 75 – 81 (2002).
W. Y. Lin, J. F. Hsieh, C. P. Lin, et al., Nucl. Med. Biol., 26, 455 – 459 (1999).
D. Niculae, V. Lungu, G. Mihailescu, et al., Rom. J. Endocrinol., 39, 45 – 52 (2001).
L. Bensimhon, T. Metaye, J. Guilhot, et al., Nucl. Med. Commun., 29, No. 11, 1015 – 1020 (2008).
V. K. Shiryaeva, V. M. Petriev, A. A. Bryukhanova, et al., Khim.-farm. Zh., 45(2), 115 – 123 (2011).
V. Lungu, D. Niculae, P. Bouziotis, et al., J. Radioanal. Nucl. Chem., 273(3), 663 – 667 (2007).
K. Liepe, R. Hliscs, J. Kropp, et al., J. Nucl. Med., 44(6), 953 – 960 (2003).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 46, No. 7, pp. 39 – 44, July, 2012.
Rights and permissions
About this article
Cite this article
Shiryaeva, V.K., Petriev, V.M., Bryukhanova, A.A. et al. Evaluation of the influence of preparation conditions on pharmacokinetics of bone-seeking radiopharmaceutical 188Re-labeled hydroxyethylidenediphosphonic acid monopotassium salt in rats. Pharm Chem J 46, 443–448 (2012). https://doi.org/10.1007/s11094-012-0818-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-012-0818-9